Optima Life Sciences Acquires Cure Medicines India Pvt. Ltd.
A strategic acquisition strengthening pharmaceutical manufacturing, formulation capabilities and Optima’s long-term vision for an integrated healthcare and life sciences platform.
Teams from Optima Life Sciences and Cure Medicines mark the beginning of the next phase together.
There comes a point when growth is no longer about doing more. It becomes about becoming more.
More capable. More relevant. More prepared for the future.
Optima Life Sciences Pvt. Ltd. has acquired Cure Medicines India Pvt. Ltd., marking a significant milestone in its journey towards building a future-ready, diversified healthcare and life sciences platform.
Founded in 2003 and based in Pune, Cure Medicines has built a strong reputation as a pharmaceutical manufacturer with capabilities spanning allopathic formulations, formulation development and quality-driven manufacturing. The acquisition adds this depth to Optima’s expanding ecosystem and supports its long-term ambition to build a stronger platform across human and animal health.
The acquisition in context
- Founded
- 2003
- Location
- Pune, India
- Core capability
- Pharmaceutical manufacturing
- Strategic role
- Expands Optima’s healthcare platform
A stronger platform for what comes next.
The acquisition strengthens Optima’s pharmaceutical capabilities, supports deeper backward integration and creates a broader base for innovation-led growth. It also brings together complementary strengths in manufacturing, formulation and market access—areas that will shape the next phase of the combined platform.
The milestone was marked in the presence of Dr. Sudipto Haldar, Director – Research, Agrivet, as chief guest. His presence reinforced the importance of science, innovation and continuous evolution as the organization prepares for its next chapter.
Why this acquisition matters
Portfolio expansion
Strengthening Optima’s presence in pharmaceutical formulations and broadening its platform across healthcare and life sciences.
Manufacturing capability
Adding established infrastructure, formulation expertise and quality systems to Optima’s expanding operating ecosystem.
Market synergy
Opening new customer segments and creating cross-market opportunities across complementary portfolios and capabilities.
Future growth
Building a more integrated platform across health, nutrition and therapeutics with science, quality and innovation at its core.
“At Optima, we have always believed in building for the long term—with a clear focus on science, quality and impact. This is not just about growth; it is about creating enduring value.”
Combining capability with strategic direction
For Cure Medicines, the transaction brings a new platform for scale while preserving the foundations built around quality, reliability and customer trust. For Optima, the combination adds manufacturing depth and formulation capability to a broader strategy centred on science-led growth.
The integration will focus on unlocking practical synergies across R&D, manufacturing, product development and market access, with the objective of creating differentiated value for customers and building a more agile operating platform.
Perspectives on the next phase
“Joining hands with Optima Life Sciences gives this legacy a powerful platform for scale and future growth.”
“The acquisition strengthens our ability to serve customers with a broader portfolio, enhanced capabilities and greater agility.”
“This is a strategic step towards building a more integrated, innovation-driven organization.”
Built on disciplined execution
Financial and operational diligence
Vikrant Mahajan, GM – Finance & Accounts, Optima Life Sciences, noted that the transaction was supported by rigorous, multi-layered due diligence covering financials, compliance, manufacturing systems and operational sustainability, with emphasis on both current performance and future scalability.
Legal and regulatory discipline
Vivek Sadhale, Co-Founder, Legalogic Consulting, who advised Optima on the transaction, highlighted the structured legal process, regulatory compliance, risk mitigation and transaction clarity that underpinned the acquisition.
Cure Medicines India Pvt. Ltd. is a Pune-based pharmaceutical manufacturer known for its diverse portfolio of allopathic formulations and established capabilities in quality-driven manufacturing and formulation development.
Visit Cure Medicines